Foamix Pharmaceuticals

February 21, 2020

Upcoming events – Filgotinib's ulcerative colitis data and serlopitant takes on pruritus

Gilead and Galapagos's filgotinib might not be a match for Rinvoq in ulcerative colitis, while Menlo needs to prove serlopitant works after previous setbacks.

Foamix Pharmaceuticals

Upcoming events – Filgotinib's ulcerative colitis data and serlopitant takes on pruritus

US FDA approval tracker: October

Go or no go? Novartis eyes a big new growth driver

Perseverance pays off for Foamix

Dermira in a spot of bother after acne failure

Upcoming events – Another SGLT2 approval due and stem cell data for Mesoblast

Strong small cap performance drives second-quarter gains

Mid-cap biopharma stocks pick up in the first quarter

Interview – Foamix spots dermatology opportunity

Snippet roundup: Wins for AcelRx, Foamix and SGLT2 developers.

IPOs surge in Q3 as investor enthusiasm shows no sign of waning

Latest Reports

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

Evaluate Vantage COVID-19 Report

Editor's Picks

Finding the next Vertex

Clinical setback lays bare Vertex’s weakness

SITC 2020 – embargo snafu triggers the first movers

Biopharma buyouts still pricey

More biotechs test the third way to market